Global Emerging Infectious Disease Diagnostics Market

Market Scope:

The global emerging infectious disease diagnostics market is projected to grow significantly, registering a CAGR of 6.7% during the forecast period (2024 – 2032).

The expansion of the market is driven by various factors, including the growing awareness of early disease detection, the global prevalence of infectious diseases, a shift from centralized laboratories to decentralized Point-of-Care (POC) testing, and technological advancements. Infectious diseases, caused by pathogens such as viruses, fungi, bacteria, or parasites, can be transmitted through direct or indirect contact, insect bites, and other means like food, soil, water, and air. Diagnosing infectious diseases involves analyzing the patient's symptoms to determine their underlying causes, which is crucial for effective treatment. The increased prevalence of infectious diseases and the rising trend of preventive medicine contribute to a higher demand for diagnostic tests, especially in regions with diverse levels of development. As a result, the market for infectious disease diagnostics is expected to continue expanding throughout the projected period.
Market Overview:
Driver: The increasing awareness and emphasis on early disease detection is driving the market growth.

Early disease detection is paramount for effective treatment and management, playing a crucial role in healthcare interventions. The timely identification of infectious diseases empowers healthcare professionals to prescribe targeted medications, implement containment measures, and prevent further disease spread. Additionally, rapid and accurate diagnostics are essential for curbing disease transmission by enabling prompt isolation, public health measures, and timely treatment within communities. The global prevalence of infectious diseases, driven by high incidence rates and the emergence of new pathogens, underscores the need for continuous advancements in diagnostic technologies. This includes innovative approaches like molecular diagnostics, next-generation sequencing, and biosensors, enhancing sensitivity, specificity, and speed. A significant shift from centralized to decentralized testing, particularly through Point-of-Care (POC) testing, responds to the demand for rapid results, especially in resource-limited settings and during outbreaks. Moreover, the increasing trend of preventive medicine fosters proactive healthcare approaches, encouraging routine screening and diagnostic testing to identify health risks before symptoms emerge. This collective emphasis on early detection and innovative diagnostic tools contributes to the growth of the emerging infectious disease diagnostics market.

Opportunities: Encouraging increased adoption of routine screening and diagnostic testing is poised to bolster the market growth in the upcoming years.

Opportunities in the emerging infectious disease diagnostics market abound, presenting avenues for growth and advancements in the field. One significant opportunity lies in the ongoing global emphasis on preventive healthcare, encouraging increased adoption of routine screening and diagnostic testing. This trend aligns with the proactive identification of potential health risks before symptoms manifest, contributing to a higher demand for infectious disease diagnostics. Additionally, the surge in infectious diseases worldwide and the continuous emergence of new pathogens create opportunities for research, development, and innovation in diagnostic technologies.

As governments respond to public health challenges, there is an opportunity for increased funding and support for initiatives related to infectious disease diagnostics, fostering advancements and accessibility. The shift towards decentralized Point-of-Care (POC) testing, driven by the need for rapid results in resource-limited settings and during outbreaks, opens avenues for novel diagnostic solutions. Collaborations between healthcare organizations, research institutions, and technology providers also present opportunities for creating integrated and comprehensive infectious disease diagnostic platforms. The market stands poised for growth as it responds to evolving global health needs, technological advancements, and the increasing recognition of the critical role of early disease detection in effective healthcare management.
Covid Impact:
The COVID-19 pandemic significantly impacted the emerging infectious disease diagnostics market, leading to a surge in demand for diagnostics and accelerating research and development efforts. The crisis prompted a notable shift towards rapid testing and Point-of-Care diagnostics, emphasizing accessibility and quick results. Supply chain disruptions affected production, and shortages of key components challenged the industry's ability to meet the heightened demand. Telemedicine gained prominence, influencing how diagnostics are administered, while governments worldwide increased funding for diagnostics to strengthen capabilities and research initiatives. The focus on multiplex testing, capable of detecting multiple pathogens simultaneously, became pronounced, and regulatory agencies streamlined processes for emergency use authorizations to expedite the approval of new diagnostic tests. The enduring effects of these changes are likely to shape the future landscape of the infectious disease diagnostics market.
Segmentation Analysis:
Significant growth is anticipated for Point-of-Care Testing during the forecast period.

Point-of-care (POC) testing for infectious diseases presents swift and on-site diagnostic capabilities, allowing for immediate detection and decision-making. These tests are crafted to be portable, user-friendly, and adaptable for deployment across diverse healthcare settings. Offering rapid results, often within minutes or hours, POC tests play a crucial role in facilitating timely diagnosis and treatment decisions, especially vital for infectious diseases where early intervention significantly influences patient outcomes and prevents further transmission. Particularly beneficial in developing countries with limited laboratory infrastructure or access to high-end capital equipment for diagnostics, POC tests aid in the timely and precise diagnosis of diseases in low-resource settings, thus contributing to alleviating the burden of infectious diseases in these regions.
Regional Analysis:
The Asia Pacific region is set to witness significant growth during the forecast period.

The Asia Pacific market for molecular diagnostics in infectious diseases is expected to experience rapid growth throughout the forecast period, propelled by heightened investments and a rise in the prevalence of infectious ailments. Factors such as government-provided healthcare benefits, increased public awareness, and a growing demand for high-quality medical care contribute to the anticipated expansion of the infectious disease molecular diagnostics market in the region. The impact of the COVID-19 pandemic has notably strained molecular diagnostics in this densely populated area, particularly in highly inhabited locations like China and India, which collectively account for approximately half of the world's population.
Competitive Analysis:
The global emerging infectious disease diagnostics market is reasonably competitive with mergers, acquisitions, and product launches. See some of the major key players in the market.

Abbott

• March 27, 2020: Abbott laboratories announced that the fastest molecular point-of-care test for the detection of novel coronavirus (COVID-19), which can yield positive results in as little as five minutes and negative results in 13 minutes, had received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA). The test will be carried out using the company's ID NOWTM platform, which offers quick results in a variety of healthcare settings, including doctor's offices, urgent care centers, and hospital emergency rooms.

bioMerieux SA

• On February 1, 2023, bioMérieux, a prominent player in in vitro diagnostics, unveiled MAESTRIATM, a cutting-edge middleware solution. Designed to serve as a central software platform, MAESTRIATM aims to streamline the workflow management of routine tasks within microbiology laboratories.

Danaher Corporation

F. Hoffmann-La Roche Ltd

Bio-Rad Laboratories, Inc.

Agilent Technologies, Inc.

Becton

Dickinson and Company

Hologic, Inc. (Gen-Probe)

Illumina, Inc.

Grifols S.A.

Qiagen

Siemens Healthineers AG

Sysmex Corporation
Scope of the Report
By Product

• Reagents, Kits and Consumables
• Instruments
• Software & Services

By Type Of Testing

• Laboratory Testing
• POC Testing

By Technology

• Immunodiagnostics
• Clinical Microbiology
• PCR
• INAAT
• DNA Sequencing & NGS
• DNA Microarray
• Other Technologies

By Disease Type

• Covid-19
• HIV
• Hepatitis
• Influenza
• Other Infectious Diseases

By End User

• Diagnostic Laboratories
• Hospital & Clinics
• Academic Research Institutes
• Other End Users

By Region

• North America (the United States & Canada)
• Europe (Germany, UK, France, Spain, Italy, and the Rest of Europe)
• Asia Pacific (China, Japan, India, and Rest of Asia Pacific)
• Rest of the World (the Middle East & Africa, and Latin America)

Keys reasons to purchasing this report

It provides a technological development map over time to understand the industry’s growth rate and indicates how the Emerging Infectious Disease Diagnostics market is evolving.

The report offers a dynamic method to various factors that drive or restrain the growth of the market and specifies which Emerging Infectious Disease Diagnostics submarket will be the main driver of the overall market from 2024 to 2032.

It renders a definite analysis of changing competitive dynamics and stipulates the leading players and what are their prospects over the forecast period.

It builds a nine-year estimate based on how the market is predicted to grow and shows what will market shares of the global region change by 2032 and which country will lead the market in 2032.